OABI OmniAb, Inc.

Nasdaq N/A


$ 1.61 $ 0.12 (8.05 %)    

Tuesday, 11-Nov-2025 15:59:54 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 1.61
$ 1.50
$ 1.39 x 1
$ 1.63 x 6,500
$ 1.48 - $ 1.63
$ 1.22 - $ 4.61
402,127
na
231.77M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-18-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-25-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-20-2022 03-31-2022 10-Q
16 03-25-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 09-23-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 omniab-lowers-fy2025-sales-guidance-from-20000m-25000m-to-18000m-22000m-vs-21657m-est

OmniAb (NASDAQ:OABI) lowers FY2025 sales outlook from $20.000 million-$25.000 million to $18.000 million-$22.000 million vs $21...

 omniab-q3-eps-014-inline-sales-2239m-miss-5644m-estimate

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 12.5 pe...

 rbc-capital-maintains-outperform-on-omniab-lowers-price-target-to-3

RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.

 correction-omniab-q2-eps-015-beats-016-estimate-sales-3897m-miss-5334m-estimate

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.4...

 omniab-affirms-fy2025-sales-guidance-of-20000m-25000m-vs-22970m-est

OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $2...

 benchmark-reiterates-buy-on-omniab-maintains-6-price-target

Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $6 price target.

 omniab-affirms-fy2025-sales-guidance-of-2000m-2500m-vs-2289m-est

OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.00 million-$25.00 million to $20.00 million-$25.00 million vs $22.89...

 omniab-q1-eps-017-misses-016-estimate-sales-415m-miss-449m-estimate

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.16) by 6...

Core News & Articles

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate program addressing two attrac...

 rbc-capital-maintains-outperform-on-omniab-lowers-price-target-to-4

RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $7 to $4.

 benchmark-maintains-buy-on-omniab-lowers-price-target-to-6

Benchmark analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and lowers the price target from $8 to $6.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION